CBIOCrescent Biopharma, Inc.
$14.10+25% 1Y
$14.10
$8.9452 weeks$26.98
What is the market doing?
Mixed
1 neutral, 2 without dataRangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
TrendRangeboundderived · Oct 8, 2026
Rangebound, no clear trend. Oversold (RSI 28). Price is −11% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CBIO is trading
Crescent Biopharma, Inc. is +25% over the past year while the S&P 500 is +18%: 6.7 points ahead of the market.
+25%
1-year return · S&P 500 +18%
- vs 200-day average
- −11%
vs 200-day average · a clear downtrend
- RSI (14)
- 28
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 48%
Below its 52-week high
Details›
- Last close2026-10-08
- $14.10
- 1 monthS&P 500 +1.6%
- −29%
- 1 yearS&P 500 +18%
- +25%
- 5 yearsS&P 500 +86%
- −106%
- vs 50-day average$16.63
- −15%
- 52-week high
- $26.98
- 52-week low
- $8.94
- Annualised volatility
- 157%
| Year | Return |
|---|---|
| 2026 (year to date) | +19% |
| 2025 | −53% |
| 2024 | −89% |
| 2023 | −15% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 4 | 3 of 4 | +5.2% |
| Feb | 4 | 1 of 4 | −6.2% |
| Mar | 4 | 2 of 4 | +3.8% |
| Apr | 4 | 3 of 4 | +3.0% |
| May | 4 | 1 of 4 | −19% |
| Jun | 4 | 1 of 4 | −9.7% |
| Jul | 4 | 0 of 4 | −17% |
| Aug | 4 | 2 of 4 | +2.5% |
| Sep | 4 | 0 of 4 | −10% |
| Oct | 5 | 3 of 5 | +30% |
| Nov | 4 | 3 of 4 | +63% |
| Dec | 4 | 2 of 4 | +8.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.